• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail

Ozurdex (dexamethasone intravitreal) implant

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)  

 

February 2014

Summary View

ADVERSE REACTIONS

6.2 Postmarketing Experience
  • retinal detachment

 

September 2012

Summary View

CONTRAINDICATIONS

4.3 Aphakic Eyes with Rupture of the Posterior Lens Capsule
  • Ozurdex is contraindicated in patients who have aphakic eyes with rupture of the posterior lens capsule.
4.4 ACIOL and Rupture of the Posterior Lens Capsule
  • Ozurdex is contraindicated in eyes with ACIOL (Anterior Chamber Intraocular Lens) and rupture of the posterior lens capsule.

ADVERSE REACTIONS

6.2 Postmarketing Experience
  • added .....complication of device insertion (implant misplacement), device dislocation with or without corneal edema, endophthalmitis, and hypotony of the eye (associated with vitreous leakage due to injection).

 

 

February 2012

Summary View

 

WARNINGS AND PRECAUTIONS

Risk of Implant Migration
  • Patients in whom the posterior capsule of the lens is absent or has a tear are at risk of implant migration into the anterior chamber.

 

ADVERSE REACTIONS

Postmarketing Experience
  • The following reactions have been identified during post-marketing use of Ozurdex in clinical practice. Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. The reactions, which have been chosen for inclusion due to either their seriousness, frequency of reporting, possible causal connection to Ozurdex or a combination of these factors, include: device dislocation and endophthalmitis.